Rubius Therapeutics, Inc. (RUBY): Price and Financial Metrics

Rubius Therapeutics, Inc. (RUBY): $0.06

0.00 (2.70%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

C

Add RUBY to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#153 of 398

in industry

RUBY Price/Volume Stats

Current price $0.06 52-week high $0.38
Prev. close $0.06 52-week low $0.00
Day low $0.06 Volume 755,800
Day high $0.06 Avg. volume 1,154,788
50-day MA $0.02 Dividend yield N/A
200-day MA $0.02 Market Cap 5.16M

RUBY Stock Price Chart Interactive Chart >


Rubius Therapeutics, Inc. (RUBY) Company Bio


Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria. It is also developing RTX-212 and RTX-4-1BBL for treatment of solid tumors; RTX-212 for hematological cancer; RTX-aAPC to treat solid and hematological cancers; and other product candidates for autoimmune disorders. The company was founded in 2013 and is based in Cambridge, Massachusetts.


RUBY Latest News Stream


Event/Time News Detail
Loading, please wait...

RUBY Latest Social Stream


Loading social stream, please wait...

View Full RUBY Social Stream

RUBY Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year 220.86%
3-year -99.55%
5-year -99.28%
YTD 5.26%
2023 -67.43%
2022 -98.19%
2021 27.54%
2020 -20.11%
2019 -40.92%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!